Methinks, a digital health Company that specializes in early detection and management of Acute Stroke (AS), using artificial intelligence (AI), today announced that it has received CE mark for its medical imaging software, Methinks Stroke Suite following a milestone year of development progress, enabling commercialization in Europe and to assist in emergency settings for the benefit of AS patients.
Dual antiplatelet treatment was noninferior to thrombolysis with regard to functional outcome at 90 days for Chinese patients with minor nondisabling stroke.
In patients with acute ischemic stroke who have not received thrombolysis or thrombectomy, early versus late antihypertensive treatment did not reduce the likelihood of death and major disability.
A combination of two drugs showed promising phase 2 results, including a reduction in cognitive impairment in patients with lacunar stroke, and may be a potential new approach to small vessel disease.
A new international trial has shown large benefits of thrombectomy in patients with ischemic strokes with a large core volume, which should lead to a change in clinical practice.